US EditionGreater Precision of HER2-Expressing Breast Cancer Treatment with 3D Pathology: New JelloX Research Collaboration
- In a study by JelloX Biotech Inc. And the National Taiwan University Hospital, over 50% of cases were reclassified as HER2-expressing using 3D pathology techniques.
- The study highlighted that more than 66.7% of patients initially classified as HER2-null were reclassified as HER2-low or HER2-ultralow after 3D testing.
- 3D pathology improves detection of HER2 in breast cancer and may enhance diagnostics for multiple cancer types, as indicated by similar results in colorectal and esophageal cancers.
- The findings highlight 3D pathology's potential to enhance diagnostic accuracy across various cancer types, supporting broader medical use.
Insights by Ground AI
Does this summary seem wrong?
33 Articles
33 Articles
All
Left
6
Center
9
Right
2
journalgazette.net+32 Reposted by 32 other sources
Greater Precision of HER2-Expressing Breast Cancer Treatment with 3D Pathology: New JelloX Research Collaboration
In the preliminary findings of a study conducted with the National Taiwan University Hospital, over 50% of sample cases were reclassified as HER2-expressing when 3D pathology was applied.
Coverage Details
Total News Sources33
Leaning Left6Leaning Right2Center9Last UpdatedBias Distribution53% Center
Bias Distribution
- 53% of the sources are Center
53% Center
L 35%
C 53%
12%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
